Hemispherx Biopharma (HEB) Reports Q2 Loss of $0.01; Reports Implementation of Austerity Measures
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Hemispherx Biopharma (NYSE: HEB) reported Q2 EPS of ($0.01), versus ($0.04) reported last year.
Hemispherx Biopharma has made changes to its senior management team and has implemented austerity measures which included the reduction of executive compensation and elimination of non-essential contractors and personnel. These measures have resulted in a significant reduction in costs and expenses. The company is now focusing on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the world.
For earnings history and earnings-related data on Hemispherx Biopharma (HEB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Steelcase (SCS) Reports Preliminary Q3 EPS In-Line with Views, Revs Light
- Medley Management (MDLY) Tops Q4 EPS by 8c
- Dominion Diamond (DDC) Reports Q3 Loss of $0.34/Share
Create E-mail Alert Related CategoriesEarnings, Hot Corp. News, Management Changes
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!